Immunotherapy-based regimen in anti-MAG neuropathy: Results in 45 patients

Haematologica

Volumn 98, Issue 12, 2013, Pages

  Hospital, Marie Anne ^a   Viala, Karine ^b   Dragomir, Sonia ^b   Levy, Vincent ^c   Cohen Aubart, Fleur ^b   Neil, Jean ^b   Musset, Lucile ^b   Choquet, Sylvain ^b   Leger, Jean Marc ^b   Leblond, Véronique ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

IgM monoclonal gammopathy; Neuropathy; Unknown significance; Waldenstrom's macroglobulinemia

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; IMMUNOGLOBULIN M; MYELIN ASSOCIATED GLYCOPROTEIN; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTI MYELIN ASSOCIATED GLYCOPROTEIN NEUROPATHY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LETTER; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; RANKIN SCALE; RELAPSE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; VERY ELDERLY;

IGM-MONOCLONAL GAMMOPATHY; NEUROPATHY; UNKNOWN SIGNIFICANCE; WALDENSTROM'S MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MYELIN-ASSOCIATED GLYCOPROTEIN; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYRADICULONEUROPATHY; RETROSPECTIVE STUDIES;

EID: 84889849357     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.087213     Document Type: Letter

References (12)

1. Steck AJ, Stalder AK, Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol. 2006;19(5):458-463.
2. Chassande B, Leger JM, Younes-Chennoufi AB, Bengoufa D, Maisonobe T, Bouche P, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve. 1998;21(1):55-62.
3. Klein CJ, Moon JS, Mauermann ML, Zeldenrust SR, Wu Y, Dispenzieri A, et al. The neuropathies of Waldenstrom's macroglobulinemia (WM) and IgM-MGUS. Can J Neurol Sci. 2011;38(2):289-295.
4. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27(1):120-126.
5. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelinassociated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2006(2):CD002827.
6. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society first revision. Journal of the Peripheral Nervous System. 2010;15(3):185-195.
7. Niermeijer JM, Eurelings M, Lokhorst HL, van der Pol WL, Franssen H, Wokke JH, et al. Rituximab for polyneuropathy with IgM monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 2009;80(9): 1036-1039.
8. Gruson B, Ghomari K, Beaumont M, Garidi R, Just A, Merle P, et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst. 2011;16(3):180-185.
9. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo-controlled trial of rituximab in IgM antimyelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65(3):286-293.
10. Leger JM, Viala K, Nicolas G, Creange A, Vallat JM, Pouget J, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80(24):2217-2225.
11. Leleu X, Tamburini J, Roccaro A, Morel P, Soumerai J, Levy V, et al. Balancing risk versus benefit in the treatment of Waldenstrom's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009;9(1):71-73.
12. Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica. 2006;91(11):1546-1550.